Xencor Inc
XNCR
$19.07
Closing
▲0.79%
1D
▼-10.17%
YTD
Market cap
$1.17B
52 week high
$28.96
52 week low
$16.49
Volume
252,703
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$1.17B
Analysts' Rating
BUY
Price Target (Mean)
39.71429
Total Analysts
14
P/E
Operating Margin
-30.88%
Beta
0.79
Revenue Growth (Annual)
-40.18%
52 week high
$28.96
52 week low
$16.49
Div. Yield
%
EPS Annual Growth
8.11
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs. It uses protein engineering capabilities to enable its understanding of protein structures and interactions and to design technologies and XmAb drug candidates with improved properties. It is advancing its XmAb drug candidates into clinical-stage development. It is focused on the Fc domain, which is part of an antibody that interacts with various segments of the immune system and controls antibody structural architecture. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Vudalimab, XmAb104, XmAb564, XmAb819, XmAb808, Plamotamab, Obexelimab, Sotrovimab, XmAb306/RG6323, and others.
